References
Pfeffer MA: The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 1993, 18(Suppl 1):430–435.
Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587.
Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.
Mann DL, Deswal A: Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. N Engl J Med 2003, 349:1963–1965.
McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293–302.
Hart RG, Sherman DG, Easton JD, Cairns JA: Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998, 51:674–681.
Hart RG: Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart 1999, 82:539–540.
Sanders P, Morton JB, Davidson NC, et al.: Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 2003, 108:1461–1468.
Rights and permissions
About this article
Cite this article
Piña, I.L. Clinical trials report. Curr Cardiol Rep 6, 159–161 (2004). https://doi.org/10.1007/s11886-004-0017-8
Issue Date:
DOI: https://doi.org/10.1007/s11886-004-0017-8